Jean A. Hurteau

Oncology

2650 Ridge Ave
Evanston, IL 60201

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

US real-world biomarker testing differences and treatment choice in advanced ovarian cancer: results of a retrospective study.

US real-world biomarker testing differences and treatment choice in advanced ovarian cancer: results of a retrospective study.

Journal: Future oncology (London, England)

Published: July 16, 2026

Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis.

Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis.

Journal: JCO precision oncology

Published: July 06, 2026

The role of platinum-free interval in advanced endometrial cancer treatment: A real-world study of 843 patients.

The role of platinum-free interval in advanced endometrial cancer treatment: A real-world study of 843 patients.

Journal: Cancer treatment and research communications

Published: January 14, 2026

Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study.

Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study.

Journal: Gynecologic oncology

Published: December 17, 2025

Identifying and breaking barriers: Addressing disparities in the care of patients with gynecologic cancers.

Identifying and breaking barriers: Addressing disparities in the care of patients with gynecologic cancers.

Journal: Gynecologic oncology reports

Published: May 12, 2025

Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer.

Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer.

Journal: Future oncology (London, England)

Published: January 17, 2025

The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

Journal: Cancer

Published: December 27, 2024

Real-world duration of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer in the United States: the CHAR1ZMA study.

Real-world duration of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer in the United States: the CHAR1ZMA study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 29, 2024

Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study.

Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study.

Journal: Oncology and therapy

Published: September 19, 2024

Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study.

Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 07, 2024

Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study.

Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study.

Journal: Oncology and therapy

Published: May 23, 2024

Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study.

Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study.

Journal: Oncology and therapy

Published: February 29, 2024

Showing 1-12 of 40

Last Updated: 09/26/2026